{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:54:55Z","timestamp":1768038895168,"version":"3.49.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12016-017-8643-2","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T22:29:48Z","timestamp":1505168988000},"page":"244-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Unmet Needs in the Pathogenesis and Treatment of Vasculitides"],"prefix":"10.1007","volume":"54","author":[{"given":"Francesco","family":"Muratore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Croci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Bonacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"8643_CR1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122\u20131128","journal-title":"Arthritis Rheum"},{"key":"8643_CR2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129\u20131134","journal-title":"Arthritis Rheum"},{"key":"8643_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.bor.0000197996.04709.4e","volume":"18","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Matteson EL (2006) Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 18:10\u201317","journal-title":"Curr Opin Rheumatol"},{"key":"8643_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, Warrington KJ (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54:463\u2013470","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/rheumatology\/kem379","volume":"47","author":"N Pipitone","year":"2008","unstructured":"Pipitone N, Versari A, Salvarani C (2008) Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford) 47:403\u2013408","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3899\/jrheum.110275","volume":"38","author":"H Direskeneli","year":"2011","unstructured":"Direskeneli H, Aydin SZ, Kermani TA et al (2011) Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 38:1471\u20131479","journal-title":"J Rheumatol"},{"issue":"4","key":"8643_CR7","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/ar2003","volume":"8","author":"M Karahaliou","year":"2006","unstructured":"Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP (2006) Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 8(4):R116","journal-title":"Arthritis Res Ther"},{"key":"8643_CR8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","volume":"17","author":"A Craven","year":"2013","unstructured":"Craven A, Robson J, Ponte C et al (2013) ACR\/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 17:619\u2013621","journal-title":"Clin Exp Nephrol"},{"key":"8643_CR9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3899\/jrheum.141144","volume":"42","author":"SZ Aydin","year":"2015","unstructured":"Aydin SZ, Direskeneli H, Sreih A et al (2015) Update on outcome measure development for large vessel vasculitis: report from OMERACT 12. J Rheumatol 42:2465\u20132469","journal-title":"J Rheumatol"},{"key":"8643_CR10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BOR.0000000000000129","volume":"27","author":"SZ Aydin","year":"2015","unstructured":"Aydin SZ, Merkel PA, Direskeneli H (2015) Outcome measures for Takayasu's arteritis. Curr Opin Rheumatol 27:32\u201337","journal-title":"Curr Opin Rheumatol"},{"key":"8643_CR11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","volume":"120","author":"GS Kerr","year":"1994","unstructured":"Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919\u2013929","journal-title":"Ann Intern Med"},{"issue":"4 Pt 2","key":"8643_CR12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.lpm.2013.01.030","volume":"42","author":"N Pipitone","year":"2013","unstructured":"Pipitone N, Pazzola G, Muratore F, Salvarani C (2013) L30. Assessment of vasculitis extent and severity. Presse Med 42(4 Pt 2):588\u2013589","journal-title":"Presse Med"},{"key":"8643_CR13","first-page":"671","volume":"87","author":"RA Luqmani","year":"1994","unstructured":"Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671\u2013678","journal-title":"QJM"},{"key":"8643_CR14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/rheumatology\/keq171","volume":"49","author":"SZ Aydin","year":"2010","unstructured":"Aydin SZ, Yilmaz N, Akar S et al (2010) Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology (Oxford) 49:1889\u20131893","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR15","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","volume":"52","author":"R Misra","year":"2013","unstructured":"Misra R, Danda D, Rajappa SM et al (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52:1795\u20131801","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR16","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3899\/jrheum.140817","volume":"42","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner F, Aydin SZ, Akar S et al (2015) Assessment of patients with Takayasu arteritis in routine practice with Indian Takayasu clinical activity score. J Rheumatol 42:1443\u20131447","journal-title":"J Rheumatol"},{"key":"8643_CR17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nrrheum.2010.82","volume":"6","author":"JC Mason","year":"2010","unstructured":"Mason JC (2010) Takayasu arteritis\u2014advances in diagnosis and management. Nat Rev Rheumatol 6:406\u2013415","journal-title":"Nat Rev Rheumatol"},{"key":"8643_CR18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234\u2013245","journal-title":"Lancet"},{"key":"8643_CR19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.berh.2016.09.010","volume":"30","author":"F Muratore","year":"2016","unstructured":"Muratore F, Pipitone N, Salvarani C, Schmidt WA (2016) Imaging of vasculitis: state of the art. Best Pract Res Clin Rheumatol 30:688\u2013706","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8643_CR20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/1744666X.2017.1285699","volume":"13","author":"F Muratore","year":"2017","unstructured":"Muratore F, Pipitone N, Salvarani C (2017) Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Rev Clin Immunol 13:345\u2013360","journal-title":"Expert Rev Clin Immunol"},{"key":"8643_CR21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","volume":"90","author":"L Martinez-Lado","year":"2011","unstructured":"Martinez-Lado L, Calvino-Diaz C, Pineiro A et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90:186\u2013193","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","volume":"93","author":"MA Alba","year":"2014","unstructured":"Alba MA, Garcia-Martinez A, Prieto-Gonzalez S et al (2014) Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 93:194\u2013201","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/39.10.1089","volume":"39","author":"E Liozon","year":"2000","unstructured":"Liozon E, Roblot P, Paire D et al (2000) Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology 39:1089\u20131094","journal-title":"Rheumatology"},{"key":"8643_CR24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703\u2013708","journal-title":"Arthritis Rheum"},{"key":"8643_CR25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"C Labarca","year":"2016","unstructured":"Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, Warrington KJ (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55:347\u2013356","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D et al (2015) Disease relapses among patients with giant cell arteritis: a prospective longitudinal cohort study. J Rheumatol 42:1213\u20131217","journal-title":"J Rheumatol"},{"key":"8643_CR27","doi-asserted-by":"crossref","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","volume":"95","author":"G Restuccia","year":"2016","unstructured":"Restuccia G, Boiardi L, Cavazza A et al (2016) Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore) 95:e3524","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR28","doi-asserted-by":"publisher","unstructured":"Comarmond C, Biard L, Lambert M et al (2017) Long-term outcomes and prognostic factors of complications in Takayasu's arteritis: a multicenter study of 318 patients. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.027094","DOI":"10.1161\/CIRCULATIONAHA.116.027094"},{"key":"8643_CR29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.mayocp.2013.04.025","volume":"88","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Kermani TA, Bacani AK, Crowson CS, Cooper LT, Matteson EL, Warrington KJ (2013) Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88:822\u2013830","journal-title":"Mayo Clin Proc"},{"key":"8643_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3899\/jrheum.140981","volume":"42","author":"S Hong","year":"2015","unstructured":"Hong S, Bae SH, Ahn SM, Lim DH, Kim YG, Lee CK, Yoo B (2015) Outcome of Takayasu arteritis with inactive disease at diagnosis: the extent of vascular involvement as a predictor of activation. J Rheumatol 42:489\u2013494","journal-title":"J Rheumatol"},{"key":"8643_CR31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1253\/circj.CJ-11-1108","volume":"76","author":"H Ohigashi","year":"2012","unstructured":"Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, Isobe M (2012) Improved prognosis of Takayasu arteritis over the past decade\u2014comprehensive analysis of 106 patients. Circ J 76:1004\u20131011","journal-title":"Circ J"},{"key":"8643_CR32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13075-016-1193-9","volume":"18","author":"S Fukui","year":"2016","unstructured":"Fukui S, Iwamoto N, Shimizu T et al (2016) Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40\u00a0years. Arthritis Res Ther 18:293","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"8643_CR33","first-page":"i60","volume":"30","author":"K Westman","year":"2015","unstructured":"Westman K, Flossmann O, Gregorini G (2015) The long-term outcomes of systemic vasculitis. Nephrol Dial Transplant 30(Suppl 1):i60\u2013i66","journal-title":"Nephrol Dial Transplant"},{"key":"8643_CR34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542\u2013548","journal-title":"Arthritis Rheum"},{"key":"8643_CR35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776\u2013784","journal-title":"Am J Kidney Dis"},{"key":"8643_CR36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KW Westman","year":"1998","unstructured":"Westman KW, Bygren PG, Olsson H et al (1998) Relapse rate, renal survival, and cancer morbidity in patients with Wegener\u2019s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9:842\u2013852","journal-title":"J Am Soc Nephrol"},{"key":"8643_CR37","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908\u20132918","journal-title":"Arthritis Rheum"},{"key":"8643_CR38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P, Cohen Tervaert JW (2015) ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 26:537\u2013542","journal-title":"J Am Soc Nephrol"},{"key":"8643_CR39","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","volume":"68","author":"LA Fussner","year":"2016","unstructured":"Fussner LA, Hummel AM, Schroeder DR et al (2016) Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheum 68:1700\u20131710","journal-title":"Arthritis Rheum"},{"key":"8643_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","volume":"19","author":"MD Morgan","year":"2017","unstructured":"Morgan MD, Szeto M, Walsh M et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 19:129","journal-title":"Arthritis Res Ther"},{"key":"8643_CR41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955\u2013960","journal-title":"Ann Rheum Dis"},{"key":"8643_CR42","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","volume":"64","author":"M Faurschou","year":"2012","unstructured":"Faurschou M, Westman K, Rasmussen N et al (2012) Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum 64:3472\u20133477","journal-title":"Arthritis Rheum"},{"key":"8643_CR43","doi-asserted-by":"publisher","unstructured":"Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211123","DOI":"10.1136\/annrheumdis-2017-211123"},{"key":"8643_CR44","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771\u20131780","journal-title":"N Engl J Med"},{"key":"8643_CR45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166\u20131173","journal-title":"Arthritis Care Res"},{"key":"8643_CR46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2017.98","volume":"13","author":"A Soriano","year":"2017","unstructured":"Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C (2017) Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 13:476\u2013484","journal-title":"Nat Rev Rheumatol"},{"key":"8643_CR47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans JM, O'Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122:502\u2013507","journal-title":"Ann Intern Med"},{"key":"8643_CR48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/annrheumdis-2013-204113","volume":"74","author":"JC Robson","year":"2015","unstructured":"Robson JC, Kiran A, Maskell J et al (2015) The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 74:129\u2013135","journal-title":"Ann Rheum Dis"},{"key":"8643_CR49","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","volume":"72","author":"TA Kermani","year":"2013","unstructured":"Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL (2013) Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence\u2014trends and prognosis. Ann Rheum Dis 72:1989\u20131994","journal-title":"Ann Rheum Dis"},{"key":"8643_CR50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2012-202145","volume":"73","author":"SL Mackie","year":"2014","unstructured":"Mackie SL, Hensor EM, Morgan AW, Pease CT (2014) Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis 73:143\u2013148","journal-title":"Ann Rheum Dis"},{"key":"8643_CR51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2016.08.015","volume":"46","author":"CL Hill","year":"2017","unstructured":"Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, Lester S (2017) Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 46:513\u2013519","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 103","key":"8643_CR52","first-page":"189","volume":"35","author":"H Direskeneli","year":"2017","unstructured":"Direskeneli H (2017) Clinical assessment in Takayasu's arteritis: major challenges and controversies. Clin Exp Rheumatol 35(Suppl 103):189\u2013193","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3899\/jrheum.121473","volume":"40","author":"PC Grayson","year":"2013","unstructured":"Grayson PC, Cuthbertson D, Carette S et al (2013) New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol 40:1905\u20131912","journal-title":"J Rheumatol"},{"issue":"Suppl 103","key":"8643_CR54","first-page":"77","volume":"35","author":"A Omma","year":"2017","unstructured":"Omma A, Erer B, Karadag O et al (2017) Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol 35(Suppl 103):77\u201382","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.rdc.2016.12.005","volume":"43","author":"L Machen","year":"2017","unstructured":"Machen L, Clowse ME (2017) Vasculitis and pregnancy. Rheum Dis Clin N Am 43:239\u2013247","journal-title":"Rheum Dis Clin N Am"},{"key":"8643_CR56","doi-asserted-by":"crossref","first-page":"A447","DOI":"10.1016\/j.autrev.2011.11.019","volume":"11","author":"M Gatto","year":"2012","unstructured":"Gatto M, Iaccarino L, Canova M, Zen M, Nalotto L, Ramonda R, Punzi L, Doria A (2012) Pregnancy and vasculitis: a systematic review of the literature. Autoimmun Rev 11:A447\u2013A459","journal-title":"Autoimmun Rev"},{"key":"8643_CR57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/BOR.0000000000000343","volume":"29","author":"E Seyahi","year":"2017","unstructured":"Seyahi E (2017) Takayasu arteritis: an update. Curr Opin Rheumatol 29:51\u201356","journal-title":"Curr Opin Rheumatol"},{"key":"8643_CR58","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/01.CIR.90.4.1855","volume":"90","author":"K Ishikawa","year":"1994","unstructured":"Ishikawa K, Maetani S (1994) Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 90:1855\u20131860","journal-title":"Circulation"},{"key":"8643_CR59","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/03009740510026526","volume":"34","author":"MC Park","year":"2005","unstructured":"Park MC, Lee SW, Park YB, Chung NS, Lee SK (2005) Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardised criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 34:284\u2013292","journal-title":"Scand J Rheumatol"},{"key":"8643_CR60","doi-asserted-by":"crossref","first-page":"e4069","DOI":"10.1097\/MD.0000000000004069","volume":"95","author":"J Li","year":"2016","unstructured":"Li J, Zhu M, Li M, Zheng W, Zhao J, Tian X, Zeng X (2016) Cause of death in Chinese Takayasu arteritis patients. Medicine (Baltimore) 95:e4069","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR61","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488\u2013494","journal-title":"Ann Rheum Dis"},{"key":"8643_CR62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17\u201328","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19\u201327","journal-title":"Medicine (Baltimore)"},{"key":"8643_CR64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle JU, Gross WL, Latza U et al (2011) Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63:257\u2013266","journal-title":"Arthritis Rheum"},{"key":"8643_CR65","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.131038","volume":"41","author":"AJ Mohammad","year":"2014","unstructured":"Mohammad AJ, Segelmark M (2014) A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 41:1366\u20131373","journal-title":"J Rheumatol"},{"key":"8643_CR66","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180\u20132188","journal-title":"J Am Soc Nephrol"},{"key":"8643_CR67","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","volume":"8","author":"AA Joode de","year":"2013","unstructured":"de Joode AA, Sanders JS, Stegeman CA (2013) Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 8:1709\u20131717","journal-title":"Clin J Am Soc Nephrol"},{"key":"8643_CR68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ctr.12084","volume":"27","author":"H Marco","year":"2013","unstructured":"Marco H, Mirapeix E, Arcos E et al (2013) Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transpl 27:338\u2013347","journal-title":"Clin Transpl"},{"key":"8643_CR69","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628\u20131636","journal-title":"J Am Soc Nephrol"},{"key":"8643_CR70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2215\/CJN.07300712","volume":"8","author":"R Goupil","year":"2013","unstructured":"Goupil R, Brachemi S, Nadeau-Fredette AC, D\u00e9ziel C, Troyanov Y, Lavergne V, Troyanov S (2013) Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8:416\u2013423","journal-title":"Clin J Am Soc Nephrol"},{"key":"8643_CR71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488\u2013498","journal-title":"Ann Intern Med"},{"key":"8643_CR72","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100\u2013105","journal-title":"J Rheumatol"},{"key":"8643_CR73","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl C, Harper L, Flossmann O et al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70:1415\u20131421","journal-title":"Ann Rheum Dis"},{"key":"8643_CR74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","volume":"74","author":"J Robson","year":"2015","unstructured":"Robson J, Doll H, Suppiah R et al (2015) Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials. Ann Rheum Dis 74:177\u2013184","journal-title":"Ann Rheum Dis"},{"key":"8643_CR75","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2014","unstructured":"Robson J, Doll H, Suppiah R et al (2014) Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 54:471\u2013481","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR76","first-page":"1283","volume":"21","author":"G Nesher","year":"1994","unstructured":"Nesher G, Sonnenblick M, Friedlander Y (1994) Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21:1283\u20131286","journal-title":"J Rheumatol"},{"key":"8643_CR77","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560\u20131567","journal-title":"Ann Rheum Dis"},{"key":"8643_CR78","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280\u20131286","journal-title":"Ann Rheum Dis"},{"key":"8643_CR79","first-page":"185","volume":"21","author":"AD Wagner","year":"2003","unstructured":"Wagner AD, Wittkop U, Prahst A, Schmidt WA, Gromnica-Ihle E, Vorpahl K, Hudson AP, Zeidler H (2003) Dendritic cells co-localize with activated CD4+ T cells in giant cell arteritis. Clin Exp Rheumatol 21:185\u2013192","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR80","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","volume":"62","author":"AP Andonopoulos","year":"2003","unstructured":"Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62:1116","journal-title":"Ann Rheum Dis"},{"key":"8643_CR81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10067-005-1115-8","volume":"25","author":"I Uthman","year":"2006","unstructured":"Uthman I, Kanj N, Atweh S (2006) Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 25:109\u2013110","journal-title":"Clin Rheumatol"},{"key":"8643_CR82","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621\u2013630","journal-title":"Ann Intern Med"},{"key":"8643_CR83","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","volume":"36","author":"NE Roche","year":"1993","unstructured":"Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286\u20131294","journal-title":"Arthritis Rheum"},{"key":"8643_CR84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.100.1.55","volume":"100","author":"M Noris","year":"1999","unstructured":"Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G (1999) Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 100:55\u201360","journal-title":"Circulation"},{"key":"8643_CR85","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017 Jul) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317\u2013328","journal-title":"N Engl J Med"},{"issue":"1 Suppl 75","key":"8643_CR86","first-page":"S59","volume":"31","author":"G Pazzola","year":"2013","unstructured":"Pazzola G, Padovano I, Boiardi L et al (2013) Tocilizumab in glucocorticoid-na\u00efve large-vessel vasculitis. Clin Exp Rheumatol 31(1 Suppl 75):S59\u2013S61","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","volume":"51","author":"C Salvarani","year":"2012","unstructured":"Salvarani C, Magnani L, Catanoso M et al (2012) Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 51:151\u2013156","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR88","first-page":"w13156","volume":"141","author":"M Seitz","year":"2011","unstructured":"Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156","journal-title":"Swiss Med Wkly"},{"key":"8643_CR89","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Segarra M, Vilardell C et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428\u20132434","journal-title":"Circulation"},{"key":"8643_CR90","unstructured":"Reichenbach S, Adler S, Cullmann J et al (2016) Tocilizumab for the treatment of giant cell arteritis\u2014MR-angiography results from the first randomized placebo-controlled trial [abstract]. Arthritis Rheum. http:\/\/acrabstracts.org\/abstract\/tocilizumab-for-the-treatment-of-giant-cell-arteritis-mr-angiography-results-from-the-first-randomized-placebo-controlled-trial\/ . Accessed 8 Sept 2017"},{"issue":"Suppl 1","key":"8643_CR91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2249.1995.tb06156.x","volume":"101","author":"JC Jennette","year":"1995","unstructured":"Jennette JC, Falk RJ (1995) Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin Exp Immunol 101(Suppl 1):18\u201322","journal-title":"Clin Exp Immunol"},{"key":"8643_CR92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5582\/irdr.2016.01014","volume":"5","author":"B Kubaisi","year":"2016","unstructured":"Kubaisi B, Abu Samra K, Foster CS (2016) Granulomatosis with polyangiitis (Wegener's disease): an updated review of ocular disease manifestations. Intractable Rare Dis Res 5:61\u201369","journal-title":"Intractable Rare Dis Res"},{"key":"8643_CR93","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.autrev.2014.08.017","volume":"13","author":"C Comarmond","year":"2014","unstructured":"Comarmond C, Cacoub P (2014) Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev 13:1121\u20131125","journal-title":"Autoimmun Rev"},{"key":"8643_CR94","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461\u20132469","journal-title":"Arthritis Rheum"},{"key":"8643_CR95","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2005.048900","volume":"65","author":"O Flossmann","year":"2006","unstructured":"Flossmann O, Jones RB, Jayne DR, Luqmani RA (2006) Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 65:841\u2013844","journal-title":"Ann Rheum Dis"},{"key":"8643_CR96","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"8643_CR97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"8643_CR98","first-page":"2017","volume":"35","author":"P Seo","year":"2008","unstructured":"Seo P, Specks U, Keogh KA (2008) Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 35:2017\u20132023","journal-title":"J Rheumatol"},{"key":"8643_CR99","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"PM Aries","year":"2006","unstructured":"Aries PM, Hellmich B, Voswinkel J et al (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853\u2013858","journal-title":"Ann Rheum Dis"},{"key":"8643_CR100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327\u2013333","journal-title":"Ann Rheum Dis"},{"key":"8643_CR101","doi-asserted-by":"crossref","first-page":"846063","DOI":"10.1155\/2010\/846063","volume":"2010","author":"A Khan","year":"2010","unstructured":"Khan A, Lawson CA, Quinn MA et al (2010) Successful treatment of ANCA-negative Wegener's granulomatosis with rituximab. Int J Rheumatol 2010:846063","journal-title":"Int J Rheumatol"},{"key":"8643_CR102","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","volume":"34","author":"M Martinez Del Pero","year":"2009","unstructured":"Martinez Del Pero M, Chaudhry A, Jones RB et al (2009) B cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort studies. Clin Otolaryngol 34:328\u2013335","journal-title":"Clin Otolaryngol"},{"key":"8643_CR103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/s10165-008-0119-z","volume":"19","author":"S Ooka","year":"2009","unstructured":"Ooka S, Maeda A, Ito H et al (2009) Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod Rheumatol 19:80\u201383","journal-title":"Mod Rheumatol"},{"issue":"4\u20135","key":"8643_CR104","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","volume":"41","author":"S Shah","year":"2015","unstructured":"Shah S, Hruskova Z, Segelmark M et al (2015) Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab. Am J Nephrol 41(4\u20135):296\u2013301","journal-title":"Am J Nephrol"},{"key":"8643_CR105","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","volume":"53","author":"P Charles","year":"2014","unstructured":"Charles P, N\u00e9el A, Tieuli\u00e9 N et al (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford) 53:532\u2013539","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR106","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310\u2013317","journal-title":"Ann Rheum Dis"},{"key":"8643_CR107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson M, Pu\u00e9chal X, Devilliers H et al (2013) Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43:60\u201369","journal-title":"J Autoimmun"},{"key":"8643_CR108","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaci.2012.05.058","volume":"131","author":"B Healy","year":"2013","unstructured":"Healy B, Bibby S, Steele R et al (2013) Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol 131:571\u2013576","journal-title":"J Allergy Clin Immunol"},{"key":"8643_CR109","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2011.155382","volume":"71","author":"A Vaglio","year":"2012","unstructured":"Vaglio A, Strehl JD, Manger B et al (2012) IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 71:390\u2013393","journal-title":"Ann Rheum Dis"},{"key":"8643_CR110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0b013e32834d85ce","volume":"24","author":"A Vaglio","year":"2012","unstructured":"Vaglio A, Moosig F, Zwerina J (2012) Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 24:24\u201330","journal-title":"Curr Opin Rheumatol"},{"key":"8643_CR111","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396\u2013401","journal-title":"Ann Rheum Dis"},{"key":"8643_CR112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jbspin.2015.04.016","volume":"83","author":"P Novikov","year":"2016","unstructured":"Novikov P, Moiseev S, Smitienko I, Zagvozdkina E (2016) Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine 83:81\u201384","journal-title":"Joint Bone Spine"},{"issue":"15","key":"8643_CR113","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar4313","volume":"24","author":"J Thiel","year":"2013","unstructured":"Thiel J, H\u00e4ssler F, Salzer U et al (2013) Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 24(15):R133","journal-title":"Arthritis Res Ther"},{"key":"8643_CR114","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","volume":"26","author":"R Cartin-Ceba","year":"2011","unstructured":"Cartin-Ceba R, Keogh KA, Specks U et al (2011) Rituximab for the treatment of Churg\u2013Strauss syndrome with renal involvement. Nephrol Dial Transplant 26:2865\u20132871","journal-title":"Nephrol Dial Transplant"},{"key":"8643_CR115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00296-009-1146-6","volume":"31","author":"KK Donvik","year":"2011","unstructured":"Donvik KK, Omdal R (2011) Churg\u2013Strauss syndrome successfully treated with rituximab. Rheumatol Int 31:89\u201391","journal-title":"Rheumatol Int"},{"key":"8643_CR116","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","volume":"47","author":"RJ Pepper","year":"2008","unstructured":"Pepper RJ, Fabre MA, Pavesio C et al (2008) Rituximab is effective in the treatment of refractory Churg\u2013Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47:1104\u20131105","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR117","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","volume":"34","author":"D Roccatello","year":"2011","unstructured":"Roccatello D, Sciascia S, Rossi D et al (2011) Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 34:175\u2013180","journal-title":"Am J Nephrol"},{"key":"8643_CR118","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/ard.2005.042937","volume":"65","author":"M Koukoulaki","year":"2006","unstructured":"Koukoulaki M, Smith HG, Jayne DR (2006) Rituximab in Churg\u2013Strauss syndrome. Ann Rheum Dis 65:557\u2013559","journal-title":"Ann Rheum Dis"},{"key":"8643_CR119","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semarthrit.2015.03.004","volume":"45","author":"A Fanouriakis","year":"2015","unstructured":"Fanouriakis A, Kougkas N, Vassilopoulos D et al (2015) Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: case report and review of current clinical evidence. Semin Arthritis Rheum 45:60\u201366","journal-title":"Semin Arthritis Rheum"},{"key":"8643_CR120","first-page":"737","volume":"33","author":"M Martinez-Villaescusa","year":"2013","unstructured":"Martinez-Villaescusa M, Lopez-Montes A, Lopez-Rubio E et al (2013) Treatment-resistant Churg\u2013Strauss syndrome: progression after five years using rituximab. Nefrologia 33:737\u2013739","journal-title":"Nefrologia"},{"key":"8643_CR121","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/ard.2009.109850","volume":"69","author":"J Saech","year":"2009","unstructured":"Saech J, Owczarczyk K, Rosgen S et al (2009) Successful use of rituximab in a patient with Churg\u2013Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 69:1254\u20131255","journal-title":"Ann Rheum Dis"},{"key":"8643_CR122","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10067-011-1756-8","volume":"30","author":"F Rees","year":"2011","unstructured":"Rees F, Yazdani R, Lanyon P (2011) Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol 30:1241\u20131245","journal-title":"Clin Rheumatol"},{"key":"8643_CR123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","volume":"24","author":"S Lovric","year":"2009","unstructured":"Lovric S, Erdbruegger U, Kumpers P et al (2009) Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 24:179\u2013185","journal-title":"Nephrol Dial Transplant"},{"key":"8643_CR124","first-page":"2015","volume":"15","author":"CE Najem","year":"2015","unstructured":"Najem CE, Yadav R, Carlson E (2015) Successful use of rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 15:2015","journal-title":"BMJ Case Rep"},{"key":"8643_CR125","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00415-013-7217-3","volume":"261","author":"L Diamanti","year":"2014","unstructured":"Diamanti L, Berzero G, Bini P et al (2014) Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). J Neurol 261:438\u2013440","journal-title":"J Neurol"},{"key":"8643_CR126","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.23791","volume":"90","author":"MP Chao","year":"2015","unstructured":"Chao MP, Hong J, Kunder C et al (2015) Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg\u2013Strauss syndrome responsive to eculizumab and rituximab. Am J Hematol 90:78\u201381","journal-title":"Am J Hematol"},{"key":"8643_CR127","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/rheumatology\/keu290","volume":"53","author":"A Grigoriou","year":"2014","unstructured":"Grigoriou A, Endean A, Sangle SR, DP D\u2032C (2014) B cell depletion therapy and eosinophilic granulomatosis with polyangiitis with hepatic involvement. Rheumatology (Oxford) 53:1741","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3109\/14397595.2013.874734","volume":"24","author":"N Umezawa","year":"2014","unstructured":"Umezawa N, Kohsaka H, Nanki T et al (2014) Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg\u2013Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG. Mod Rheumatol 24:685\u2013687","journal-title":"Mod Rheumatol"},{"key":"8643_CR129","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970\u20132982","journal-title":"Arthritis Rheum"},{"key":"8643_CR130","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.2005.047308","volume":"65","author":"VV Kaushik","year":"2006","unstructured":"Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg\u2013Strauss syndrome. Ann Rheum Dis 65:1116\u20131117","journal-title":"Ann Rheum Dis"},{"key":"8643_CR131","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/0971-4065.161021","volume":"26","author":"S Baikunje","year":"2016","unstructured":"Baikunje S, Vankalakunti M, Upadhyaya VS, Hosmane GB (2016) Eosinophilic granulomatosis with polyangiitis with severe pulmonary hemorrhage treated with rituximab. Indian J Nephrol 26:142\u2013144","journal-title":"Indian J Nephrol"},{"key":"8643_CR132","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545\u2013553","journal-title":"Eur J Intern Med"},{"key":"8643_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"J Jennette","year":"2013","unstructured":"Jennette J, Falk R, Bacon P et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"8643_CR134","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","volume":"62","author":"C Ribi","year":"2010","unstructured":"Ribi C, Cohen P, Pagnoux C et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186\u20131197","journal-title":"Arthritis Rheum"},{"key":"8643_CR135","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","volume":"44","author":"M Gayraud","year":"2001","unstructured":"Gayraud M, Guillevin L, le Toumelin P et al (2001) Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666\u2013675","journal-title":"Arthritis Rheum"},{"key":"8643_CR136","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.27240","volume":"62","author":"C Pagnoux","year":"2010","unstructured":"Pagnoux C, Seror R, Henegar C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616\u2013626","journal-title":"Arthritis Rheum"},{"key":"8643_CR137","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rbr.2015.07.003","volume":"55","author":"LS Da Silva","year":"2015","unstructured":"Da Silva LS, De Campos KV, de Melo AK et al (2015) Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review. Rev Bras Reumatol 55:531\u2013535","journal-title":"Rev Bras Reumatol"},{"key":"8643_CR138","first-page":"1","volume":"12","author":"Y Seri","year":"2015","unstructured":"Seri Y, Shoda H, Hanata N et al (2015) A case of refractory polyarteritis nodosa successfully treated with rituximab. Mod Rheumatol 12:1\u20133","journal-title":"Mod Rheumatol"},{"key":"8643_CR139","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1111\/j.1756-185X.2012.01733.x","volume":"15","author":"S Krishnan","year":"2012","unstructured":"Krishnan S, Bhakuni DS, Kartik S (2012) Rituximab in refractory cutaneous polyarteritis. Int J Rheum Dis 15:e127","journal-title":"Int J Rheum Dis"},{"key":"8643_CR140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/RHU.0b013e31823a58d7","volume":"17","author":"A N\u00e9el","year":"2011","unstructured":"N\u00e9el A, Masseau A, Hervier B et al (2011) Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol 17:439\u2013441","journal-title":"J Clin Rheumatol"},{"key":"8643_CR141","doi-asserted-by":"crossref","first-page":"687547","DOI":"10.1155\/2010\/687547","volume":"2010","author":"NK Bansal","year":"2010","unstructured":"Bansal NK, Houghton KM (2010) Cutaneous polyarteritis nodosa in childhood: a case report and review of the literature. Arthritis 2010:687547","journal-title":"Arthritis"},{"key":"8643_CR142","doi-asserted-by":"crossref","first-page":"738293","DOI":"10.1155\/2009\/738293","volume":"2009","author":"E Ribeiro","year":"2009","unstructured":"Ribeiro E, Cressend T, Duffau P et al (2009) Rituximab efficacy during a refractory polyarteritis nodosa flare. Case Rep Med 2009:738293","journal-title":"Case Rep Med"},{"key":"8643_CR143","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","volume":"48","author":"D Eleftheriou","year":"2009","unstructured":"Eleftheriou D, Melo M, Marks SD et al (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48:978\u2013986","journal-title":"Rheumatology (Oxford)"},{"key":"8643_CR144","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3109\/s10165-012-0732-8","volume":"23","author":"T Zoshima","year":"2013","unstructured":"Zoshima T, Matsumura M, Suzuki Y et al (2013) A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade. Mod Rheumatol 23:1029\u20131033","journal-title":"Mod Rheumatol"},{"key":"8643_CR145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.rhu.0000173225.41933.83","volume":"11","author":"J Feinstein","year":"2005","unstructured":"Feinstein J, Arroyo R (2005) Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 11:219\u2013222","journal-title":"J Clin Rheumatol"},{"key":"8643_CR146","doi-asserted-by":"crossref","unstructured":"Tous-Romero F, Rodr\u00edguez-Almaraz E, Rodr\u00edguez-Peralto JL, Postigo-Llorente C (2017) Polyarteritis nodosa with a systemic inflammatory response pattern: effectiveness of anti-TNF. Actas Dermosifiliogr","DOI":"10.1016\/j.adengl.2017.07.008"},{"issue":"4","key":"8643_CR147","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/14397595.2013.874737","volume":"24","author":"L Valor","year":"2014","unstructured":"Valor L, Monteagudo I, de la Torre I et al (2014) Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept. Mod Rheumatol 24:(4)688\u2013689","journal-title":"Mod Rheumatol"},{"key":"8643_CR148","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fphar.2014.00122","volume":"5","author":"M Capuozzo","year":"2014","unstructured":"Capuozzo M, Ottaiano A, Nava E et al (2014) Etanercept induces remission of polyarteritis nodosa: a case report. Front Pharmacol 5:122","journal-title":"Front Pharmacol"},{"key":"8643_CR149","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2169\/internalmedicine.56.8235","volume":"56","author":"S Matsuo","year":"2017","unstructured":"Matsuo S, Hayashi K, Morimoto E et al (2017) The successful treatment of refractory polyarteritis nodosa using infliximab. Intern Med 56:1435\u20131438","journal-title":"Intern Med"},{"issue":"6 Suppl 32","key":"8643_CR150","first-page":"S138","volume":"21","author":"C Garcia-Porrua","year":"2003","unstructured":"Garcia-Porrua C, Gonzalez-Gay MA (2003) Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis. Clin Exp Rheumatol 21(6 Suppl 32):S138","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR151","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfk082","volume":"21","author":"K Wu","year":"2006","unstructured":"Wu K, Throssell D (2006) A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 21:1710\u20131712","journal-title":"Nephrol Dial Transplant"},{"key":"8643_CR152","first-page":"1371","volume":"32","author":"J Al-Bishri","year":"2005","unstructured":"Al-Bishri J, le Riche N, Pope JE (2005) Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 32:1371\u20131373","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"8643_CR153","doi-asserted-by":"crossref","first-page":"ii79","DOI":"10.1136\/ard.2004.028498","volume":"63","author":"EC Keystone","year":"2004","unstructured":"Keystone EC (2004) The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 63(Suppl 2):ii79\u2013ii83","journal-title":"Ann Rheum Dis"},{"key":"8643_CR154","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-3083.2006.01967.x","volume":"21","author":"J Vega Gutierrez","year":"2007","unstructured":"Vega Gutierrez J, Rodriguez Prieto MA, Garcia Ruiz JM (2007) Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 21:570\u2013571","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8643_CR155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jbspin.2013.11.009","volume":"81","author":"R Campanilho-Marques","year":"2014","unstructured":"Campanilho-Marques R, Ramos F, Canh\u00e3o H, Fonseca JE (2014) Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab. Joint Bone Spine 81:277\u2013278","journal-title":"Joint Bone Spine"},{"key":"8643_CR156","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1542\/peds.2009-3331","volume":"126","author":"DM Wahezi","year":"2010","unstructured":"Wahezi DM, Gomes WA, Ilowite NT (2010) Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment. Pediatrics 126:e719\u2013e722","journal-title":"Pediatrics"},{"key":"8643_CR157","first-page":"277","volume":"10","author":"Y Braun-Moscovici","year":"2008","unstructured":"Braun-Moscovici Y, Markovits D, Rozin A et al (2008) Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 10:277\u2013281","journal-title":"Isr Med Assoc J"},{"key":"8643_CR158","unstructured":"Soriano A, Pipitone N, Salvarani C Cardiac involvement in Beh\u00e7et disease. In: The heart in rheumatic, autoimmune and inflammatory diseases. Elsevier Ed. ISBN: 978-0-12-803267-1 | Feb 28, 2017"},{"issue":"24","key":"8643_CR159","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1073\/pnas.1406575111","volume":"111","author":"MJ Ombrello","year":"2014","unstructured":"Ombrello MJ, Kirino Y, de Bakker PI, Kastner DL, Remmers EF (2014) Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated toxicity. Proc Natl Acad Sci U S A 111(24):8867\u20138872","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8643_CR160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.47.2.157","volume":"47","author":"N Dilsen","year":"1988","unstructured":"Dilsen N, Konice M, Aral O et al (1988) Behcet's disease associated with amyloidosis in Turkey and in the world. Ann Rheum Dis 47:157\u2013163","journal-title":"Ann Rheum Dis"},{"key":"8643_CR161","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1002\/art.24149","volume":"58","author":"A Mahr","year":"2008","unstructured":"Mahr A, Belarbi L, Wechsler B et al (2008) Population-based prevalence study of Behcet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 58:3951\u20133959","journal-title":"Arthritis Rheum"},{"key":"8643_CR162","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG et al (2007) Epidemiology and clinical course of Behcet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum 57:171\u2013178","journal-title":"Arthritis Rheum"},{"key":"8643_CR163","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","volume":"61","author":"KT Calamia","year":"2009","unstructured":"Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM (2009) Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study. Arthritis Rheum 61:600\u2013604","journal-title":"Arthritis Rheum"},{"key":"8643_CR164","first-page":"488","volume":"150","author":"CC Zouboulis","year":"1999","unstructured":"Zouboulis CC (1999) Epidemiology of Adamantiades-Behcet's disease. Ann Med Interne (Paris) 150:488\u2013498","journal-title":"Ann Med Interne (Paris)"},{"key":"8643_CR165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-9-42","volume":"9","author":"L Savey","year":"2014","unstructured":"Savey L, Resche-Rigon M, Wechsler B et al (2014) Ethnicity and association with disease manifestations and mortality in Behcet's disease. Orphanet J Rare Dis 9:42","journal-title":"Orphanet J Rare Dis"},{"key":"8643_CR166","first-page":"1152","volume":"105","author":"H Behcet","year":"1937","unstructured":"Behcet H (1937) \u00dcber rezidivierende, aphth\u00f6se, durch ein virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152\u20131157","journal-title":"Dermatol Wochenschr"},{"key":"8643_CR167","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/1756-185X.12520","volume":"18","author":"F Davatchi","year":"2015","unstructured":"Davatchi F, Sadeghi AB, Chams-Davatchi C et al (2015) The saga of diagnostic\/classification criteria in Behcet's disease. Int J Rheum Dis 18:594\u2013605","journal-title":"Int J Rheum Dis"},{"key":"8643_CR168","unstructured":"Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990; 335:1078\u201380"},{"key":"8643_CR169","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/33.2.115","volume":"33","author":"TW O'Neill","year":"1994","unstructured":"O'Neill TW, Rigby AS, Silman AJ, Barnes C (1994) Validation of the International Study Group criteria for Behcet's disease. Br J Rheumatol 33:115\u2013117","journal-title":"Br J Rheumatol"},{"key":"8643_CR170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2014.01.014","volume":"48-49","author":"H Yazici","year":"2014","unstructured":"Yazici H, Yazici Y (2014) Criteria for Beh\u00e7et\u2019s disease with reflections on all disease criteria. J Autoimmun 48-49:104\u2013107","journal-title":"J Autoimmun"},{"key":"8643_CR171","doi-asserted-by":"crossref","unstructured":"The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28:338\u201347","DOI":"10.1111\/jdv.12107"},{"issue":"Suppl. 102","key":"8643_CR172","first-page":"S175","volume":"34","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Leccese P, Christensen R et al (2016) A systematic literature review on the treatment of major organ involvement of Beh\u00e7et\u2019s syndrome informing the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol 34(Suppl. 102):S175","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 102","key":"8643_CR173","first-page":"S143","volume":"34","author":"G Guzelant","year":"2016","unstructured":"Guzelant G, Ucar D, Hatemi G et al (2016) Earlier use of infliximab for the uveitis of Beh\u00e7et\u2019s syndrome appears to be associated with better outcome. Clin Exp Rheumatol 34(Suppl. 102):S143","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 012","key":"8643_CR174","first-page":"S3","volume":"34","author":"SN Esatoglu","year":"2016","unstructured":"Esatoglu SN, Hatemi G, Leccese P (2016) Olivieri I. Highlights of the 17th International Conference on Beh\u00e7et\u2019s syndrome. Matera, Italy, 15-17 September 2016. Clin Exp Rheumatol 34(Suppl 012):S3\u2013S9","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 102","key":"8643_CR175","first-page":"S187","volume":"34","author":"G Lopalco","year":"2016","unstructured":"Lopalco G, Emmi G, Gentileschi S et al (2016) Certolizumab pegol treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective observational study. Clin Exp Rheumatol 34(Suppl. 102):S187","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR176","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/exd.12927","volume":"25","author":"A Tsianakas","year":"2016","unstructured":"Tsianakas A, Brunner PM, Ghoreschi K et al (2016) The single-chain anti-TNF antibody DLX105 induces clinical and biomarkers responses upon local administration in patients with chronic plaque-type psoriasis. Exp Dermatol 25:428\u2013433","journal-title":"Exp Dermatol"},{"issue":"Suppl. 102","key":"8643_CR177","first-page":"S188","volume":"34","author":"T Xenitidis","year":"2016","unstructured":"Xenitidis T, Berger C, Jung T, Henes J, Koetter I (2016) Effective and rapid treatment of flares in patients with Beh\u00e7et\u2019s disease by the single chain anti-TNF antibody DLX105. Clin Exp Rheumatol 34(Suppl. 102):S188","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR178","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R et al (2015) Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study. N Engl J Med 372:1510\u20131518","journal-title":"N Engl J Med"},{"key":"8643_CR179","doi-asserted-by":"crossref","first-page":"370e375","DOI":"10.1016\/j.autrev.2014.12.009","volume":"14","author":"M Touzot","year":"2015","unstructured":"Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D (2015) IFN-a induces IL-10 production and tilt the balance between Th1 and Th17 in Beh\u00e7et disease. Autoimmun Rev 14:370e375","journal-title":"Autoimmun Rev"},{"key":"8643_CR180","doi-asserted-by":"crossref","first-page":"154e159","DOI":"10.3109\/s10165-009-0246-1","volume":"20","author":"Z Habibagahi","year":"2010","unstructured":"Habibagahi Z, Habibagahi M, Heidari M (2010) Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Beh\u00e7et's disease. Mod Rheumatol 20:154e159","journal-title":"Mod Rheumatol"},{"key":"8643_CR181","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","volume":"82","author":"A Mirouse","year":"2017","unstructured":"Mirouse A, Barete S, Monfort JB et al (2017) Ustekinumab for Beh\u00e7et\u2019s disease. J Autoimmun 82:41\u201346","journal-title":"J Autoimmun"},{"key":"8643_CR182","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G et al (2015) Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol 34:1293\u20131301","journal-title":"Clin Rheumatol"},{"key":"8643_CR183","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"C Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Beh\u00e7et disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"key":"8643_CR184","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology 228:211\u2013214","journal-title":"Dermatology"},{"issue":"Suppl. 102","key":"8643_CR185","first-page":"S182","volume":"34","author":"C Capittini","year":"2016","unstructured":"Capittini C, De Silvestri C, De Silvestri A, Scotti V, Scudelleri L, Tinelli C (2016) Systematic review of the literature for the use of intravenous immunoglobulins in Beh\u00e7et disease. Clin Exp Rheumatol 34(Suppl. 102):S182","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 102","key":"8643_CR186","first-page":"S182","volume":"34","author":"C Capittini","year":"2016","unstructured":"Capittini C, De Amici M, De Silvestri A (2016) Plasma cytokines as biomarkers for clinical response during nine months of intravenous immunoglobulins therapy in a Beh\u00e7et disease patient unsuitable for immunosuppression. Clin Exp Rheumatol 34(Suppl. 102):S182","journal-title":"Clin Exp Rheumatol"},{"key":"8643_CR187","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"LS Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Borhani HA (2012) Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report. Clin Neurol Neurosurg 114:297\u2013298","journal-title":"Clin Neurol Neurosurg"},{"key":"8643_CR188","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","volume":"44","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Pipitone N, Pazzola G, Salvarani C (2015) Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et. Semin Arthritis Rheum 44:472\u2013475","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-017-8643-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:00:41Z","timestamp":1750874441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-017-8643-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":188,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["8643"],"URL":"https:\/\/doi.org\/10.1007\/s12016-017-8643-2","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}